These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 38308655

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
    Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ, ARROYO Study Investigators .
    Br J Dermatol; 2024 Jul 16; 191(2):187-199. PubMed ID: 38367194
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study.
    Jin BH, Hong T, Yoo BW, Kim CO, Kim D, Kim YN, Park MS.
    Clin Transl Sci; 2024 Oct 16; 17(10):e70032. PubMed ID: 39432406
    [Abstract] [Full Text] [Related]

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S, Staubach P, Pasha M, Singh B, Chang AT, Bernstein JA, Rasmussen HS, Siebenhaar F, Maurer M.
    J Allergy Clin Immunol; 2022 May 01; 149(5):1683-1690.e7. PubMed ID: 34954198
    [Abstract] [Full Text] [Related]

  • 7. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study.
    Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M.
    J Allergy Clin Immunol; 2009 Mar 01; 123(3):672-9. PubMed ID: 19201016
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
    Antonijoan R, García-Gea C, Puntes M, Pérez J, Esbrí R, Serra C, Fortea J, Barbanoj MJ.
    Clin Ther; 2007 May 01; 29(5):814-822. PubMed ID: 17697901
    [Abstract] [Full Text] [Related]

  • 11. Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands.
    Wang Y, Scheffel J, Vera CA, Liu W, Günzel D, Terhorst-Molawi D, Maurer M, Altrichter S.
    Front Immunol; 2022 May 01; 13():955161. PubMed ID: 35967390
    [Abstract] [Full Text] [Related]

  • 12. Acetylcholine-induced whealing in cholinergic urticaria - What does it tell us?
    Altrichter S, Wang Y, Schumacher P, Alraboni O, Church MK, Maurer M.
    J Dermatol Sci; 2021 Jul 01; 103(1):10-15. PubMed ID: 34049770
    [Abstract] [Full Text] [Related]

  • 13. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Yagami A, Stjepanovic A, Radin A, Staudinger HW, Patel N, Amin N, Akinlade B, Fan C, Bauer D, Yancopoulos GD, Patel K, Mannent LP, Laws E.
    J Allergy Clin Immunol; 2024 Jul 01; 154(1):184-194. PubMed ID: 38431226
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
    Ortonne JP, Grob JJ, Auquier P, Dreyfus I.
    Am J Clin Dermatol; 2007 Jul 01; 8(1):37-42. PubMed ID: 17298105
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL).
    Ruft J, Asady A, Staubach P, Casale T, Sussmann G, Zuberbier T, Maurer M, Weller K, Altrichter S.
    Clin Exp Allergy; 2018 Apr 01; 48(4):433-444. PubMed ID: 29369455
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria.
    Altrichter S, Salow J, Ardelean E, Church MK, Werner A, Maurer M.
    J Dermatol Sci; 2014 Aug 01; 75(2):88-93. PubMed ID: 24837213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.